A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab

NCT06042049 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: Nirsevimab

Sponsor

AstraZeneca

Collaborators

IQVIA Pty Ltd